Page 32 - CIBERER-2015-eng

Platforms
CIBERER BIOBANK
We now sum up the main activities and results in line with the objectives defined in the 2015 Action Plan:
OBJECTIVE 1: TO SUPPLY THE BIOBANK WITH BIOLOGICAL SAMPLES
The total number of samples of RD collected at the end of 2015 is over 400, covering more than 30 different pathologies. (http://www.ciberer-biobank.es).
OBJECTIVE 2: TO FURTHER A PLAN OF STRATE- GIC ALLIANCES AND DISSEMINATION
Cooperation:
• Member of the Red Valenciana de Biobancos (RVB).
• Cooperation Agreement with the FISABIO bi- obank for Biomedical Research and Public Health.
• Framework agreement with the National DNA Bank.
• Member of several work groups of the Red Na- cional de Biobancos.
• Agreement with the Fundación FEDER for con- tracting technical staff for backing the develop- ment of the technique for generating human iPS.
• Contract with ABF Pharmaceutical Services GmbH.
Measures for publicising the work done by the Biobank:
‘Investigar es Avanzar’, 8th Annual CIBERER Meeting, 4th Scientific Meeting of TREAT-CMT, 6th National Congress of Biobanks, Master in Bio- banks at the UCV and the RNB.
OBJECTIVE 3: GENERATING ADDED VALUE FOR CIBERER GROUPS.
Services provided
In 2015 the Biobank made ready new services for analysing the integrity of DNA and traceability (genetic fingerprint) provided at no cost to CIBER- ER researchers along with the services that it had already been providing (processing and custody of samples, ethical-legal advice, management of collection, implementation of quality manage- ment systems, etc.).
It has also gone on working on the development of other services (myoblast cultures, generating iPS cells, etc.).
In 2015 22 samples were provided and a wide range of services for processing and keeping samples, cell immortalisation and advice for CI- BERER groups were given.
OBJECTIVE 4: FOSTERING AND SUPPORTING NEW LINES OF ACTION IN RARE DISEASES
Participation in projects:
• FP7 HEALTH 2012-INNOVATION: RD-Connect: An integrated platform connecting registries, biobanks and clinical bioinformatics for RD.
• Translational Research, Experimental Medici- ne and Therapeutics on Charcot Marie Tooth, TREAT-CMT. In cooperation with CIBERER units U732, U755, U733, U713, U743, process- ing a good deal of the associated samples.
• Participation, along with CIBERER unit U730 in an international project for studying Wolfram syndrome, assuming responsibility for manag- ing samples.
• Influence of epigenetic factors on the devel- opment of Adolescent Idiopathic Scoliosis. Dr García (U733). Call for 2012 Grants by the Fun- dación Mapfre.
• AMER – Acción Multidisciplinar en Enferme- dades Raras y Medicina Personalizada. FED- ER-INNTERCONECTA Programme. 2012-14. The Biobank is taking part in PT2: Registers of patients, biobanks and knowledge manage- ment.
• Spanish Exomes Project, SPANEX. This project is financed with CIBERER funds involving 9 CI- BERER groups, giving logistics support for col- lecting and storing samples, as well as advice on ethical/legal aspects.
• Development and validation of possible bio- markers and therapeutic targets for Friedre- ich’s ataxia. IP: Dr Díaz-Nido (U748). Partici- pating groups: U732 and U733. The Biobank cooperates by providing samples and giving advice in ethical/legal aspects.
32 I Annual report 2015 I CIBERER